Vemurafenib in non-small-cell lung cancer patients with BRAF and BRAF mutations.
Fiche publication
Date publication
février 2020
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie, Dr FAVIER Laure
Tous les auteurs :
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY
Lien Pubmed
Résumé
BRAF mutations occurring in 1%-5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (INCA) launched the AcSé vemurafenib trial to assess the efficacy and safety of vemurafenib in cancers with various BRAF mutations. We herein report the results of the NSCLC cohort.
Mots clés
BRAF, basket trial, biomarker, lung cancer, personalised therapy, vemurafenib
Référence
Ann. Oncol.. 2020 Feb;31(2):289-294